Tolerable Duration of Warm Ischaemia After Circulatory Death Is Safe For At Least One Hour in Porcine Lungs: Functional Assessment with Ex Vivo Lung Perfusion
Keywords:Donation after circulatory death, lung donation, Ex-vivo lung perfusion, warm ischemia, animal experimental model
Background: Lungs from donation after circulatory death (DCD) may be an underused resource for transplantation. The aim was to investigate, with a DCD pig model, if it was possible to recondition lungs exposed for up to 2 h of warm ischaemia with ex vivo lung perfusion (EVLP).
Methods: Danish domestic pigs (N = 17) were randomized into three groups. In the two study groups, lungs were exposed to either 1 or 2 h of warm ischaemia. All lungs were reconditioned and evaluated after 83 ± 38 minutes of perfusion at FiO2 1.0 and 0.21 with EVLP. Outcome measures were gas exchange, pulmonary physiology, inflammatory markers, and histopathologic assessment score.
Results: Lungs exposed for 2 h of warm ischaemia did not meet the criteria: PaO2 > 13 kPa required for donation compared with lungs subjected to 0 and 1 h of warm ischaemia (11.0 kPa vs. 14.2 kPa, P < 0.001). These lungs also developed an increased amount of foam and fluid in the airways. No differences in PaCO2, compliance, or pulmonary vascular resistance were observed.
Conclusion: Results show that while lungs subjected to 0 or 1 h of warm ischaemia meet the criteria for transplantation based on EVLP evaluation, lungs subjected to 2 h of warm ischaemia did not.
Boffini M, Ricci D, Ranieri VM, et al. 2015. A bridge over troubled waters. Transplant int. 28(3):284-285.
Botha P, Rostron AJ, Fisher AJ, et al. 2008. Current Strategies in Donor Selection and Management. Semin Thorac Cardiovasc Surg. 20(2):143-151.
Charles EJ, Mehaffey JH, Huerter ME, et al. 2018. Ex vivo assessment of porcine donation after circulatory death lungs that undergo increasing Warm Ischemia times. Transpl Direct. 4(12):e405.
Cypel M, Yeung JC, Liu M, et al. 2011. Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation. N Engl J Med. 364(15):1431-1440.
Egan TM, Lambert CJ, Reddick R, et al. 1991. A strategy to increase the donor pool: Use of cadaver lungs for transplantation. Ann Thorac Surg. 52(5):1113-1120.
Haam S, Lee S, Paik HC, et al. 2015. The effects of hydrogen gas inhalation during ex vivo lung perfusion on donor lungs obtained after cardiac death. Eur J Cardiothorac Surg. 48(4):542-547.
Hytting-Andreasen R, Balk-Møller E, Hartmann B, et al. 2018. Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. PLoS ONE. 13(6):e0198046.
Inci I. 2017. Donors after cardiocirculatory death and lung transplantation. J Thorac Dis. 9(8):2660-2669.
Kootstra G, Daemen JHC, Oomen APA. 1995. Categories of non-heart-beating donors. Transpl Proc. (27):2893-2894.
Machuca TN, Cypel M, Keshavjee S. 2013. Advances in lung preservation. Surg Clin North Am. 93(6):1373-1394.
Nilsson T, Wallinder A, Henriksen I. 2019. Lung transplantation after ex vivo lung perfusion in two Scandinavian centres. Eur J Cardiothorac Surg. 1;55(4):766-772.
Porteous MK, Lee JC. 2017. Primary Graft Dysfunction After Lung Transplantation. Clin Chest Med. 38(4):641-654.
Raemdonck DEM Van, Jannis NCP, Leyn PRJ De, et al. 1998. Warm lschemic Tolerance in Collapsed Pulmonary Grafts Is Limited to 1 Hour. Ann Thorac Surg. 228(6):788–796.
Spratt JR, Mattison LM, Iaizzo PA, et al. 2017. An experimental study of the recovery of injured porcine lungs with prolonged normothermic cellular ex vivo lung perfusion following donation after circulatory death. Transpl Int. 30(9):932-944.
Spratt JR, Mattison LM, Iaizzo PA, et al. 2018. Lung transplant after prolonged ex vivo lung perfusion: predictors of allograft function in swine. Transpl Int. 31(12):1405-1417.
van Suylen V, Luijk B, Hoek RAS, et al. 2017. A Multicenter Study on Long-Term Outcomes After Lung Transplantation Comparing Donation After Circulatory Death and Donation After Brain Death. Am J Transpl. 17(10):2679-2686.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).